Pharmaceutical Technology1h
Risk adjusted net present value: What is the current valuation of Ionis Pharmaceuticals’s Ulefnersen Sodium?
Ulefnersen Sodium is an antisense oligonucleotide commercialized by Ionis Pharmaceuticals, with a leading Phase III program in Amyotrophic Lateral Sclerosis.
Pharmaceutical Technology1h
Risk adjusted net present value: What is the current valuation of Neurocrine Biosciences’s NBI-1076986?
NBI-1076986 is a small molecule commercialized by Neurocrine Biosciences, with a leading Phase I program in Movement Disorders.
Pharmaceutical Technology1h
Risk adjusted net present value: What is the current valuation of Artiva Biotherapeutics’s GCC-4001?
GCC-4001 is a cell therapy commercialized by Artiva Biotherapeutics, with a leading Phase II program in B-Cell Non-Hodgkin Lymphoma.
Pharmaceutical Technology2h
Risk adjusted net present value: What is the current valuation of Cardiol Therapeutics’s Cannabidiol 1?
Cannabidiol 1 is a small molecule commercialized by Cardiol Therapeutics, with a leading Phase II program in Pericarditis.
Pharmaceutical Technology1h
Risk adjusted net present value: What is the current valuation of Prime Medicine’s PM-359?
PM-359 is a gene-modified cell therapy commercialized by Prime Medicine, with a leading Phase II program in Chronic Granulomatous Disease.
Pharmaceutical Technology1h
Risk adjusted net present value: What is the current valuation of Immuneering’s IMM-1-104?
IMM-1-104 is a small molecule commercialized by Immuneering, with a leading Phase II program in Pancreatic Cancer.
Pharmaceutical Technology2h
Risk adjusted net present value: What is the current valuation of Armata Pharmaceuticals’s APSA-02?
APSA-02 is a biologic commercialized by Armata Pharmaceuticals, with a leading Phase II program in Bacteremia.
Pharmaceutical Technology2h
Risk adjusted net present value: What is the current valuation of I-Mab’s Givastomig?
The revenue for Givastomig is expected to reach an annual total of $48 mn by 2040 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to ...
Pharmaceutical Technology2h
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co’s Mazisotine?
Mazisotine is a small molecule commercialized by Eli Lilly and Co, with a leading Phase II program in Diabetic Neuropathic Pain.
Pharmaceutical Technology2h
Risk adjusted net present value: What is the current valuation of Intra-Cellular Therapies’s ITI-333?
ITI-333 is a small molecule commercialized by Intra-Cellular Therapies, with a leading Phase I program in Opium (Opioid) Addiction.